Fred Hutch scientists conduct hundreds of clinical trials and volunteer studies, often in collaboration with the University of Washington, Seattle Children’s and Seattle Cancer Care Alliance, our clinical care partner.
Our researchers are conducting a number of therapeutic and non-therapuetic COVID-19 studies including treatment trials, observational studies and vaccine trials.
To end this pandemic, we need volunteers of all ages, races, ethnicities and backgrounds to participate in research studies. That includes volunteers who have had a COVID-19 diagnosis and those who have never had a COVID-19 diagnosis.
Volunteer participation in clinical trials and observational studies is vital to disease research. No matter how promising a new drug, vaccine or procedure looks when tested in the laboratory or on animals, it cannot be approved for general use in humans until it has been carefully evaluated through several phases of clinical study that include volunteer participants. Through our clinical trials, patients gain access to promising new treatments for cancer and other diseases, as well as new vaccines for diseases such as HIV.
Observational studies are also crucial to determining cause and effect in human health, including how behavior, lifestyle, genetic factors and other traits may help prevent disease or contribute to disease risk. Some of our studies seek healthy participants for prevention research that may involve dietary changes, vitamin supplementation, increased physical activity or adoption of other health-promoting behaviors.
Below are studies that are still enrolling participants. Some involve healthy volunteers, and some seek patients with particular diagnoses or medical histories. Each study describes its enrollment criteria in detail, and many offer online screening tools for prospective participants.
The study is testing an oral investigational medicine for the treatment of COVID-19, the illness caused by SARS-CoV-2 coronavirus. The trial will evaluate the safety, tolerability, and efficacy of EIDD-2801 to eliminate SARS-CoV-2 viral RNA detection in persons with COVID-19.
The study is testing an infusion of REGN-COV2, a combination of two antibodies against SARS-CoV-2, the virus that causes COVID-19, to see whether they can: (1) decrease the amount of virus in the body; (2) decrease the length of time the virus is in the body; and (3) decrease the length and severity of COVID-19 illness. The antibodies in this study cannot give you SARS-CoV-2.
The primary objectives of this study are to evaluate the efficacy of remdesivir (RDV) in reducing the rate of hospitalization or death in non-hospitalized participants with early stage COVID-19 and to evaluate the safety of RDV administered in an outpatient setting.
The Seattle Vaccine Trials Unit, part of Fred Hutch, is looking for volunteers to take part in research studies for people who are at risk for COVID or have tested positive for COVID-19. Individuals are needed to help us learn more about how the virus affects the immune system.
We are enrolling HIV-negative volunteers for a number of HIV vaccine studies. The products used in our trials are not produced from live HIV or from HIV-infected human cells and cannot cause HIV infection.
Recruiting individuals likely exposed to coronavirus. Help fight COVID-19! If you live or work in an environment with high-risk of exposure to the novel coronavirus, please consider joining our study today.
The study is testing an infusion of VIR-7831 monoclonal antibody against SARS-CoV-2 to determine whether it can decrease the rate of progression. The antibodies in this study cannot give you SARS-CoV-2.
Fred Hutch Survivorship Program is recruiting childhood transplant recipients, parents and caregivers to a study to lean more about what is easy or hard when returning to school after a transplant.
Fred Hutch Survivorship Program is recruiting young adult cancer survivors to a study to learn more about the impact of cancer therapy on employment and work-related quality of life.
We are recruiting participants for a study of the immune system. Help us learn how the immune system of healthy individuals and patients with compromised immune systems respond to an inactivated vaccine.
This 12-week pilot study will research the effects of healthy eating on biomarkers in blood and breast density. You may be eligible for this study if you are female, aged 18-30 and have not had children.
If you are interested in this study, complete a survey first.
Some studies have shown that frequent eating is associated with lower risk for certain diseases, while other studies suggest that eating the standard three meals a day is better. We are recruiting healthy adults between the ages of 18 to 50 to participate in a a study that examines how eating patterns influence health and appetite.
Fred Hutch is recruiting patient with leukemia or related blood disorders who have relapsed after blood or marrow transplant to a phase 1 treatment study. Eligible participants may be offered a new type of cell therapy.
We are currently recruiting about 200 people to participate in our study. We hope that this study may provide information to help with designing a vaccine for Rhinovirus or for other viruses. Rhinoviruses are responsible for causing 30-50% of common colds.
Prostate Cancer Active Lifestyle (PALS) is enrolling volunteers with low-grade prostate cancer who have chosen active surveillance of their disease. The goal is to learn whether weight loss through diet and exercise can slow the progression of prostate cancer.
We are working to develop vaccines and medicines to prevent and limit malaria. To do this, we need healthy volunteers to take part in our clinical research studies. Read the general criteria and use our screening tool to see if you qualify for a study.
We are seeking both HIV-positive and HIV-negative volunteers for observational studies that help us learn more about the immune system. No medications or vaccines will be given.
We are enrolling HIV-negative volunteers for studies on how the mucosal immune system works and how people become infected with HIV through sex. Participants will make one clinic visit and provide a swabbed sample from their mucous membranes.